Dyne Therapeutics Inc (NASDAQ: DYN) on Monday, plunged -4.99% from the previous trading day, before settling in for the closing price of $35.24. Within the past 52 weeks, DYN’s price has moved between $6.40 and $47.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 24.75%. With a float of $75.30 million, this company’s outstanding shares have now reached $100.40 million.
The extent of productivity of a business whose workforce counts for 141 workers is very important to gauge. In terms of profitability, gross margin is 48.52%, operating margin of -7156.28%, and the pretax margin is -6800.4%.
Dyne Therapeutics Inc (DYN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Dyne Therapeutics Inc is 25.00%, while institutional ownership is 84.30%. The most recent insider transaction that took place on Oct 16 ’24, was worth 836,770. In this transaction Director of this company sold 23,671 shares at a rate of $35.35, taking the stock ownership to the 99,652 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 13,013 for $35.17, making the entire transaction worth $457,667. This insider now owns 86,639 shares in total.
Dyne Therapeutics Inc (DYN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 24.75% per share during the next fiscal year.
Dyne Therapeutics Inc (NASDAQ: DYN) Trading Performance Indicators
Dyne Therapeutics Inc (DYN) is currently performing well based on its current performance indicators. A quick ratio of 26.63 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.58, a number that is poised to hit -0.72 in the next quarter and is forecasted to reach -3.21 in one year’s time.
Technical Analysis of Dyne Therapeutics Inc (DYN)
The latest stats from [Dyne Therapeutics Inc, DYN] show that its last 5-days average volume of 0.89 million was inferior to 1.54 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 69.60%. Additionally, its Average True Range was 1.74.
During the past 100 days, Dyne Therapeutics Inc’s (DYN) raw stochastic average was set at 41.56%, which indicates a significant decrease from 48.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.83% in the past 14 days, which was lower than the 77.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.30, while its 200-day Moving Average is $31.08. Now, the first resistance to watch is $34.51. This is followed by the second major resistance level at $35.54. The third major resistance level sits at $36.07. If the price goes on to break the first support level at $32.94, it is likely to go to the next support level at $32.41. The third support level lies at $31.38 if the price breaches the second support level.
Dyne Therapeutics Inc (NASDAQ: DYN) Key Stats
Market capitalization of the company is 3.36 billion based on 87,383K outstanding shares. Right now, sales total 0 K and income totals -235,940 K. The company made 0 K in profit during its latest quarter, and -65,100 K in sales during its previous quarter.
